Klaus Mörike
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Klaus Mörike has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
C. H. Gleiter
Universitätsklinikum Tübingen
3 shared publicationsC.H. Gleiter
Universitätsklinikum Tübingen
1 shared publicationCh. H. Gleiter
Abteilung Klinische Pharmakologie, Institut für Pharmakologie und Toxikologie, Universitätsklinikum Tübingen
1 shared publicationDirk Moßhammer
Division of General Practice, University Hospital Tübingen, Tübingen, D-72074, Germany
1 shared publicationElke Schaeffeler
Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology Stuttgart D‐70376 Germany
1 shared publicationJ. R. Sindermann
1 shared publication
Latest Publications
- 11 December 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (6) , 45-49
Herausforderungen der Tuberkulosetherapie
- 11 December 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (6) , 45-49
Herausforderungen der Tuberkulosetherapie
- 14 October 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (5) , 12
P2X3-Rezeptor-Antagonisten — eine Renaissance für wirksame Antitussiva?
- 14 October 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (5) , 12
P2X3-Rezeptor-Antagonisten — eine Renaissance für wirksame Antitussiva?
- Open Access
- 1 September 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (4) , 27
Vitamin-D-Gabe beschleunigt die Sputumkonversion bei Tbc nicht
- 1 September 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (4) , 27
Open AccessVitamin-D-Gabe beschleunigt die Sputumkonversion bei Tbc nicht
- 27 June 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (3) , 31
Roflumilast on top reduziert Exazerbationen
- 27 June 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (3) , 31
Roflumilast on top reduziert Exazerbationen
- 25 April 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (2) , 24
Tyrosinkinasehemmer als Hoffnungsträger?
- 25 April 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (2) , 24
Tyrosinkinasehemmer als Hoffnungsträger?
- 25 February 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (1) , 26-27
IL-5-Antikörper hilft, Steroide einzusparen
- 25 February 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (1) , 26-27
IL-5-Antikörper hilft, Steroide einzusparen
- 25 February 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (1) , 24
Wachstumsfaktorblockade verlängert auch hier das Überleben
- 25 February 2015
- Published by Springer Nature in Pneumo-News
- Vol. 7 (1) , 24
Wachstumsfaktorblockade verlängert auch hier das Überleben
- 23 October 2014
- Published by Springer Nature in Pneumo-News
- Vol. 6 (1) , 22
TSLP – ein neues Target bei allergischem Asthma?
- 23 October 2014
- Published by Springer Nature in Pneumo-News
- Vol. 6 (1) , 22
TSLP – ein neues Target bei allergischem Asthma?
- 11 October 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (11) , 1361-1366
Pflanzliche Arzneimittel
- 11 October 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (11) , 1361-1366
Pflanzliche Arzneimittel
- 21 August 2014
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 78 (3) , 454-466
Mechanisms and assessment of statin‐related muscular adverse effects
Statin‐associated muscular adverse effects cover a wide range of symptoms, including asymptomatic increase of creatine kinase serum activity and life‐threatening rhabdomyolysis. Different underlying pathomechanisms have been proposed. However, a unifying concept of the pathogenesis of statin‐related muscular adverse effects has not emerged so far. In this review, we attempt to categorize these mechanisms along three levels. Firstly, among pharmacokinetic factors, it has been shown for some statins that inhibition of cytochrome P450‐mediated hepatic biotransformation and hepatic uptake by transporter proteins contribute to an increase of systemic statin concentrations. Secondly, at the myocyte membrane level, cell membrane uptake transporters affect intracellular statin concentrations. Thirdly, at the intracellular level, inhibition of the 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase results in decreased intracellular concentrations of downstream metabolites (e.g. selenoproteins, ubiquinone, cholesterol) and alteration of gene expression (e.g. ryanodine receptor 3, glycine amidinotransferase). We also review current recommendations for prescribers.
- 21 August 2014
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 78 (3) , 454-466
Mechanisms and assessment of statin‐related muscular adverse effects
Statin‐associated muscular adverse effects cover a wide range of symptoms, including asymptomatic increase of creatine kinase serum activity and life‐threatening rhabdomyolysis. Different underlying pathomechanisms have been proposed. However, a unifying concept of the pathogenesis of statin‐related muscular adverse effects has not emerged so far. In this review, we attempt to categorize these mechanisms along three levels. Firstly, among pharmacokinetic factors, it has been shown for some statins that inhibition of cytochrome P450‐mediated hepatic biotransformation and hepatic uptake by transporter proteins contribute to an increase of systemic statin concentrations. Secondly, at the myocyte membrane level, cell membrane uptake transporters affect intracellular statin concentrations. Thirdly, at the intracellular level, inhibition of the 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase results in decreased intracellular concentrations of downstream metabolites (e.g. selenoproteins, ubiquinone, cholesterol) and alteration of gene expression (e.g. ryanodine receptor 3, glycine amidinotransferase). We also review current recommendations for prescribers.